Brexpiprazole patent expiry?

Brexpiprazole (brand name Brep) is protected by a family of patents covering its core chemical structure, formulations, manufacturing processes and certain specific use claims.
Because patents are issued by many different jurisdictions, the “expiry” you’ll see on a US‑patent database is just one part of the overall protection picture. The U.S. Patent & Trademark Office (USPTO) issues a composition‑of‑matter patent for the core chemical (the “brexpiprazole” molecule) and a separate use/indication patent for treating schizophrenia or bipolar disorder, among others.

Below is a concise overview of the key U.S. patents that are most relevant to generic entry, along with their estimated expiry dates as of the time this answer was written (2026‑09‑25):

What do these dates mean for generics?

Because generic manufacturers must be confident that no patent will be infringed, the earliest practical entry for a generic brexpiprazole is usually slated for the year 2028–2029**. The exact launch date can shift due to:

1. Patent litigation – A brand‑owner can file a patent interference or patent‑in‑franchise action that can delay